<DOC>
	<DOC>NCT02746471</DOC>
	<brief_summary>The Reveal LINQ Registry will generate reliable long-term "real world" data of product performance, economic valuation, site-of-service procedural information.</brief_summary>
	<brief_title>Reveal LINQ Registry</brief_title>
	<detailed_description>The study is a prospective, non-randomized, observational, multi-center, global study. The study will characterize clinical actions initiated by Reveal LINQ arrhythmia detection and estimate procedure-related acute infection rate. Approximately 1,500 subjects will be implanted with a Reveal LINQ ICM and undergo continuous remote monitoring and be followed prospectively from insertion through 18 months.</detailed_description>
	<mesh_term>Arrhythmias, Cardiac</mesh_term>
	<criteria>Subject or legally authorized representative provides written authorization and/or consent per institution and geographical requirements. Subject is intended to receive or be treated with the have a Reveal LINQ ICM inserted in the next 30 days. Patient enrolled before or on the same date of insertion of the Reveal LINQ ICM Subject consent prior to ICM insertion Subject who is, or is expected to be inaccessible for followup Subject with exclusion criteria required by local law Subject is currently enrolled in or plans to enroll a concurrent study that may confound the results of this study. Coenrollment in any concurrent drug and/or device clinical study (including registries) requires approval of the study manager or designee.</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>